Duchnowska Renata
Klinika Onkologii Wojskowego Instytutu Medycznego w Warszawie.
Pneumonol Alergol Pol. 2010;78(6):439-44.
Standard management of advanced non-small cell lung cancer includes palliative chemotherapy, but its efficacy is modest. In most cases a few cycles of palliative chemotherapy are administered, as there is no evidence of benefit associated with prolonged treatment. Recently, there is an interest in a new approach including treatment continuation using cytotoxic compounds of proved efficacy in second-line treatment, such as docetaxel and pemetrexed, or targeted agents (erlotinib, gefitinib, cetuximab and bevacizumab). This review presents the current knowledge on this therapeutic strategy including the results of most relevant phase III studies and their metaanalyses.
晚期非小细胞肺癌的标准治疗包括姑息化疗，但其疗效一般。在大多数情况下，仅进行几个周期的姑息化疗，因为没有证据表明延长治疗会带来益处。最近，人们对一种新方法产生了兴趣，该方法包括使用在二线治疗中已证明有效的细胞毒性化合物（如多西他赛和培美曲塞）或靶向药物（厄洛替尼、吉非替尼、西妥昔单抗和贝伐单抗）继续进行治疗。这篇综述介绍了关于这种治疗策略的当前知识，包括最相关的III期研究结果及其荟萃分析。
